Pfizer pays $135M to ease Exubera pain

Exubera fallout alert: Pfizer has reached a deal with its partner on the drug, Nektar Therapeutics. The drug giant will pay Nektar $135 million for its trouble. And if Nektar finds a new partner to help it develop the inhaled insulin product, Pfizer will hand over all its rights to the new venture.

Meanwhile, Consort Medical, which made plastic applicators for the product, is shutting a plant and laying off 165. The manufacturing facility, located in Milton Keynes, England, will be sold.

You'll recall that Pfizer took a $2.8 billion charge against earnings in the third quarter to pay for pulling the plug on the once-so-promising Exubera.

- check out Pfizer's release
- see this report on Nektar from CNN Money
- read about Consort's consolidation in Plastics & Rubber Weekly

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.